Movement Alert｜Abivax S.A. Intraday Rise 5.01% in Regular Trading, rebound follows fading impact of post-H1 target price cuts

Market Focus10-15

On October 15, Abivax S.A. rose 5.01% in Regular Trading, trading near $91.5/share, with turnover of $29.9998 million.

The most recent market-moving backdrop indicates the stock advanced as the impact from analyst target price reductions following its H1 results appeared to fade.

Earlier disclosures showed Abivax reported H1 EPS of $(2.43), below the $(1.08) consensus estimate, while sales of $2.959 million exceeded the $1.860 million estimate. After that release, Wedbush cut its target price from $160 to $118 and maintained a Neutral rating, while Truist also lowered its target. The latest trading move suggests that pressure tied to those revisions has moderated, even as investors continue to weigh the earnings miss against stronger-than-expected revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment